Andrew P. Blanchard

647 total citations
8 papers, 535 citations indexed

About

Andrew P. Blanchard is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Andrew P. Blanchard has authored 8 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Andrew P. Blanchard's work include Drug Transport and Resistance Mechanisms (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Pharmacological Effects and Toxicity Studies (2 papers). Andrew P. Blanchard is often cited by papers focused on Drug Transport and Resistance Mechanisms (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Pharmacological Effects and Toxicity Studies (2 papers). Andrew P. Blanchard collaborates with scholars based in United States and Netherlands. Andrew P. Blanchard's co-authors include David M. Stresser, Charles L. Crespi, Stephanie D. Turner, Vaughn P. Miller, John C. L. Erve, Andre Dandeneau, Shangara S. Dehal, Christopher Patten, Raman Sharma and R. J. H. Clark and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Drug Metabolism and Disposition and European Journal of Pharmaceutical Sciences.

In The Last Decade

Andrew P. Blanchard

8 papers receiving 518 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew P. Blanchard United States 6 351 144 140 99 67 8 535
Andre Dandeneau United States 5 304 0.9× 141 1.0× 103 0.7× 83 0.8× 58 0.9× 7 426
Konstantine W. Skordos United States 9 301 0.9× 164 1.1× 168 1.2× 87 0.9× 38 0.6× 10 501
Michael A. Mohutsky United States 18 437 1.2× 210 1.5× 164 1.2× 93 0.9× 68 1.0× 34 716
Margit Spatzenegger Austria 8 385 1.1× 157 1.1× 185 1.3× 117 1.2× 71 1.1× 13 562
Stephanie D. Turner United States 7 439 1.3× 170 1.2× 214 1.5× 118 1.2× 80 1.2× 9 738
Anna-Karin Sohlenius-Sternbeck Sweden 12 282 0.8× 212 1.5× 171 1.2× 99 1.0× 41 0.6× 22 594
Jackie C. Bloomer United Kingdom 13 268 0.8× 180 1.3× 261 1.9× 54 0.5× 58 0.9× 20 751
Sabrina X. Zhao United States 11 418 1.2× 164 1.1× 229 1.6× 151 1.5× 86 1.3× 12 656
Matthew A. Cerny United States 14 349 1.0× 218 1.5× 170 1.2× 99 1.0× 61 0.9× 25 655
Timothy J. Strelevitz United States 9 402 1.1× 248 1.7× 237 1.7× 58 0.6× 75 1.1× 13 722

Countries citing papers authored by Andrew P. Blanchard

Since Specialization
Citations

This map shows the geographic impact of Andrew P. Blanchard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew P. Blanchard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew P. Blanchard more than expected).

Fields of papers citing papers by Andrew P. Blanchard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew P. Blanchard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew P. Blanchard. The network helps show where Andrew P. Blanchard may publish in the future.

Co-authorship network of co-authors of Andrew P. Blanchard

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew P. Blanchard. A scholar is included among the top collaborators of Andrew P. Blanchard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew P. Blanchard. Andrew P. Blanchard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Purohit, Vivek S., Kazuko Sagawa, Hao‐Jui Hsu, et al.. (2024). Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form. Clinical Pharmacology & Therapeutics. 116(4). 996–1004. 5 indexed citations
2.
Chen, Raymond, et al.. (2021). Developing a Biorelevant Dissolution Method for an Extrudable Core System (ECS) Osmotic Tablet. AAPS PharmSciTech. 23(1). 5–5. 1 indexed citations
3.
Kushner, Joseph, Manisha Lamba, Thomas Stock, et al.. (2019). Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology. European Journal of Pharmaceutical Sciences. 147. 105200–105200. 17 indexed citations
4.
Zhang, George, Shangara S. Dehal, Jennifer Johnson, et al.. (2006). HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81. Drug Metabolism and Disposition. 34(5). 734–737. 34 indexed citations
5.
Stresser, David M., Andrew P. Blanchard, Raman Sharma, et al.. (2004). HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE. Drug Metabolism and Disposition. 32(1). 105–112. 115 indexed citations
6.
Blanchard, Andrew P., Beverly Nickerson, Linda Lohr, et al.. (2004). Identification of low-level degradants from low dose tablets. Journal of Pharmaceutical and Biomedical Analysis. 36(2). 265–275. 4 indexed citations
7.
Stresser, David M., Stephanie D. Turner, Andrew P. Blanchard, Vaughn P. Miller, & Charles L. Crespi. (2002). Cytochrome P450 Fluorometric Substrates: Identification of Isoform-Selective Probes for Rat CYP2D2 and Human CYP3A4.. Drug Metabolism and Disposition. 30(7). 845–852. 139 indexed citations
8.
Stresser, David M., Andrew P. Blanchard, Stephanie D. Turner, et al.. (2000). Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates. Drug Metabolism and Disposition. 28(12). 1440–1448. 220 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andre Dandeneau Breakdown of academic impact, for papers by Konstantine W. Skordos Breakdown of academic impact, for papers by Michael A. Mohutsky Breakdown of academic impact, for papers by Margit Spatzenegger Breakdown of academic impact, for papers by Stephanie D. Turner Breakdown of academic impact, for papers by Anna-Karin Sohlenius-Sternbeck Breakdown of academic impact, for papers by Jackie C. Bloomer Breakdown of academic impact, for papers by Sabrina X. Zhao Breakdown of academic impact, for papers by Matthew A. Cerny Breakdown of academic impact, for papers by Timothy J. Strelevitz
Rankless by CCL
2026